

**Minutes of the September 9, 2011
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division**

Members present

Rick Holm, MD, Debra Farver, PharmD; Dana Darger, RPh

Members absent

Timothy Soundy, MD; Bill Ladwig, RPh; James Engelbrecht, MD

DSS staff present

Mike Jockheck, RPh

HID staff present

Candace Rieth, PharmD

Administrative Business

The P&T meeting was called to order by R. Holm at approximately 1:08pm. The minutes of the June 10, 2011 meeting were presented. D. Farver made a motion to approve. R. Holm seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

C. Rieth presented an overview of the prior authorization (PA) activity for June 2011. There were a total of 1,838 PAs processed in the month of June, with 96.95% of those requests responded to in less than 8 hours. There were 1,395 (85%) requests received electronically and 242 (15%) requests received by fax.

Analysis of the Top 15 Therapeutic Classes

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 04/01/2011 – 06/30/2011. The top five classes were antipsychotics, cerebral stimulants, amphetamines, adrenals, and antidepressants. The top 15 therapeutic classes make up 40.51% of total claims. C. Rieth also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 13.31% of total claims. D. Farver made a suggestion that the P&T committee review medications used to treat ADHD at the next meeting. This item will be added to the agenda for December.

Ophthalmic Antihistamine Review

The committee placed ophthalmic antihistamines on prior authorization at the March meeting. C. Rieth presented the prior authorization form. E. Byrnes, representing Alcon, spoke regarding Patanol and Pataday. A motion was made by D. Farver to add Patanol to the list of ophthalmic antihistamines that require a prior authorization. R. Holm seconded the motion. The motion was approved unanimously.

Less Sedating Antihistamines

The committee asked that less sedating antihistamines be reviewed with recent changes in the class; Allegra gaining OTC status. There was no public comment. A motion was made by D. Farver to place all OTC antihistamines on prior authorization for recipients 18 years of age and older and to place chewable antihistamines on prior authorization for recipients under the age of 18. R. Holm seconded the motion. The motion was approved unanimously.

Colcrys Review

A recommendation was made at the June meeting to review Colcrys and include colchicine data. This topic was tabled.

Medications used to treat RLS Review

C. Rieth presented clinical information for medications used to treat RLS. B. Felt, representing GSK, spoke regarding Horizant. A motion was made by D. Farver to place Horizant on prior authorization with criteria including 1) diagnosis 2) quantity limit of 600mg per day and 3) failure on other agents. A bullet point should be added to the form that gabapentin and benzodiazepines do not require a prior authorization. R. Holm seconded the motion. The motion passed unanimously.

Nexiclon Review

C. Rieth presented clinical information for Nexiclon. There was no public comment. D. Farver made a motion to place Nexiclon on prior authorization with failure of clonidine as the criteria for coverage. R. Holm seconded the motion. The motion passed unanimously.

Medications used to treat Hepatitis C Review

C. Rieth presented clinical information for medications used to treat Hepatitis C. C. Gillespie, representing Merck, spoke regarding Victrelis. L. Borland, representing Vertex, spoke regarding Incivek. A motion was made by D. Farver to place Incivek and Victrelis on prior authorization with criteria including 1) verification of triple therapy and 2) genotype 1. R. Holm seconded the motion. The motion passed unanimously. A prior authorization form will be brought to the December meeting for board approval.

Topical Acne Agents Review

C. Rieth presented clinical information for topical acne agents. There was no public comment. A motion was made by D. Farver to place topical acne agents on prior authorization with criteria including failure of generic acne agents. R. Holm seconded the motion. The motion passed unanimously.

Gralise Review

C. Rieth presented clinical information for Gralise. There was no public comment. A motion was made by R. Holm to place Gralise on prior authorization with criteria including 1) failure of gabapentin and 2) trial to last 3 months. The motion was seconded by D. Farver. The motion passed unanimously.

Dificid Review

C. Rieth presented clinical information for Dificid. There was no public comment. A motion was made by D. Farver to place Dificid on prior authorization with criteria including failure of Vancomycin. R. Holm seconded the motion. The motion passed unanimously.

The next meeting date is scheduled for December 9, 2011. The location will be updated on the website as soon as possible. A motion was made by R. Holm at 2:50pm to adjourn the SD Medicaid P&T meeting. D. Farver seconded the motion. Motion passed unanimously and the meeting was adjourned.